LGALS2

Galectin-2 · P05162 · LGALS2 on Sugi Atlas →

147 patent compounds predicted against LGALS2, 122 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL17993073 SCHEMBL17993073 0.53 2/20
SCHEMBL19665299 SCHEMBL19665299 0.53 2/20
SCHEMBL19681042 SCHEMBL19681042 0.53 2/20
SCHEMBL19681090 SCHEMBL19681090 0.53 2/20
SCHEMBL23435225 SCHEMBL23435225 0.53 2/20
SCHEMBL23435260 SCHEMBL23435260 0.53 2/20
SCHEMBL21851777 SCHEMBL21851777 0.50 2/20
SCHEMBL24086075 SCHEMBL24086075 0.50 2/20
SCHEMBL19089985 SCHEMBL19089985 0.39 2/20
SCHEMBL15150623 SCHEMBL15150623 1.00 1/20
SCHEMBL16227464 SCHEMBL16227464 1.00 1/20
SCHEMBL16231583 SCHEMBL16231583 1.00 1/20
SCHEMBL16227328 SCHEMBL16227328 0.80 1/20
SCHEMBL16227420 SCHEMBL16227420 0.80 1/20
SCHEMBL16231584 SCHEMBL16231584 0.80 1/20
SCHEMBL16231585 SCHEMBL16231585 0.80 1/20
SCHEMBL16234124 SCHEMBL16234124 0.80 1/20
SCHEMBL16234129 SCHEMBL16234129 0.80 1/20
SCHEMBL16227348 SCHEMBL16227348 0.78 1/20
SCHEMBL16231590 SCHEMBL16231590 0.78 1/20

Clinical trials — most relevant to LGALS2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction PHASE3WITHDRAWN
A Phase 2 Extension of Study GCS-100-CS-4003 PHASE2WITHDRAWN
A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes PHASE2UNKNOWN
A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease PHASE2COMPLETED
Vitamin D Deficiency Treatment Outcomes After Non-ST-Segment Elevation Myocardial Infarction PHASE2UNKNOWN
A Phase 2 Extension Study of Study GCS-100-CS-4002 PHASE2COMPLETED
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients PHASE1COMPLETED
The Diagnostic Value of Serum Oncostatin M and Galactin 3 as Biomarkers in Diagnosis of Ulcerative Colitis Disease nanNOT_YET_RECRUITING
Biomarkers for Risk Stratification After STEMI nanUNKNOWN
A Wearable Device and AI-Supported Diet and Exercise Intervention nanRECRUITING
Urinary G3BP as a Novel Biomarker in Lupus Nephritis nanNOT_YET_RECRUITING
Galectin-3 for Thromboembolic Formation in Patients With Atrial Fibrillation CHA₂DS₂-VASc Scoring nanUNKNOWN
A Serum Galectin-3 Levels in Placenta Accreta Spectrum Pregnancies nanCOMPLETED
Galectin and Respiratory Weaning nanUNKNOWN
Effect of Low-Glycemic Index Mediterranean Diet on AGEs nanCOMPLETED
ARrhythmias in MYocarditis nanUNKNOWN
Galectin-3 Binding Protein in Cardiovascular Disease and Chronic Heart Failure nanCOMPLETED
Galectin-3 Blockade in Patients With High Blood Pressure nanCOMPLETED
Galectin-3 as a Biomarker in Patients With Chagas Disease nanCOMPLETED
The Role of Galectins in the Non-invasive Diagnosis of Endometriosis nanUNKNOWN
Galectin 3 Dosage in Diagnosis of Nodular and Multinodular Goiter nanCOMPLETED
Testicular Proteins for Sperm Retrieval Prediction Protein1, Testis-Expressed Gene 101, and Lectin Galactoside-binding Protein in Predicting Surgical Sperm Retrieval in Men With Non-Obstructive Azoospermia nanUNKNOWN
Galectin-3 in Septic and Non-septic Acute Kidney Injury nanUNKNOWN
Blood Collection From Heart Failure Patients to Evaluate for Galectin-3 Measurement Differences Using Various Collection Tubes nanCOMPLETED
Evaluation of Galectin-3 in Serum and Saliva of Pemphigus Patients nanUNKNOWN
Evaluation of Serum Galectin-9 Level in Systemic Lupus Erythematosus Patients and it's Association With Disease Activity and Organ Damage nanUNKNOWN
Left Bundle Branch Pacing on Outcomes and Ventricular Remodeling in Biventricular CRT Nonresponders nanRECRUITING
Serum Galectin-3 as a Marker of Human Papillomavirus Infection nanCOMPLETED
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes nanCOMPLETED
ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a LGALS2 binder may also engage these)

ProteinNameSimilarity
Q9Z144 0.988 Q9Z144 →
Q9CQW5 0.983 Q9CQW5 →
P11762 0.975 P11762 →
P48538 0.974 P48538 →
Q5R7M1 0.974 Q5R7M1 →
C0HJR3 0.974 C0HJR3 →
P16045 0.973 P16045 →
C0HJQ1 0.972 C0HJQ1 →
P81184 0.971 P81184 →
Q49I35 0.970 Q49I35 →
P11116 0.968 P11116 →
LGALS1 Galectin-1 0.966 landscape →
P23668 0.963 P23668 →
P07583 0.960 P07583 →
P97590 0.955 P97590 →
O54891 0.950 O54891 →
LGALS8 Galectin-8 0.948 landscape →
Q9UHV8 0.946 Q9UHV8 →
Q62665 0.945 Q62665 →
P36573 0.945 P36573 →
O54974 0.944 O54974 →
Q05315 0.942 Q05315 →
Q29058 0.940 Q29058 →
Q9JL15 0.939 Q9JL15 →
P47967 0.939 P47967 →
Q8TCE9 0.939 Q8TCE9 →
Q6DKI2 0.938 Q6DKI2 →
P56217 0.938 P56217 →
O44126 0.937 O44126 →
LGALS4 Galectin-4 0.936 landscape →